Mepolizumab (NUCALA®) is an antibody targeting interleukin (IL)-5, a cytokine that regulates eosinophils, which has been approved for the treatment of EGPA. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.